Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: Initial insights

被引：5

作者：

Hofer, Matthias P. ^{[1
]}

Criscuolo, Paola ^{[1
]}

Shah, Nilay ^{[2
]}

ter Wal, Anne L. J. ^{[1
]}

Barlow, James ^{[1
]}

机构：

[1] Imperial Coll Business Sch, London, England

[2] Imperial Coll London, Dept Chem Engn, London, England

来源：

FRONTIERS IN MEDICINE | 2022年 / 9卷

关键词：

medicines regulation; pharmaceutical innovation; United Kingdom; Brexit; health policy; Medicines and Healthcare products Regulatory Agency; DRUGS;

D O I：

10.3389/fmed.2022.1011082

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Brexit was presented as an opportunity to promote innovation by breaking free from the European Union regulatory framework. Since the beginning of 2021 the Medicines and Healthcare products Regulatory Agency (MHRA) has operated as the independent regulatory agency for the United Kingdom. The MHRA's regulatory activity in 2021 was analyzed and compared to that of other international regulatory bodies. The MHRA remained reliant on EU regulatory decision-making for novel medicines and there were significant regulatory delays for a small number of novel medicines in the UK, the reasons being so far unclear. In addition, the MHRA introduced innovation initiatives, which show early promise for quicker authorization of innovative medicines for cancer and other areas of unmet need. Longer-term observation and analysis is needed to show the full impact of post-Brexit pharmaceutical regulatory policy.

引用

页数：10

共 50 条

[31] Quasi (-social) citizenship, the common travel area, and the fragmented protection of employment rights in the United Kingdom after Brexit
O'Connor, Niall
EUROPEAN LABOUR LAW JOURNAL, 2024, 15 (02) : 319 - 345
[32] Do green innovation and financial globalization contribute to the ecological sustainability and energy transition in the United Kingdom? Policy insights from a bootstrap rolling window approach
Ramzan, Muhammad
Razi, Ummara
Quddoos, Muhammad Umer
Adebayo, Tomiwa Sunday
SUSTAINABLE DEVELOPMENT, 2023, 31 (01) : 393 - 414
[33] Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom
Woodall, Alan A.
Abuzour, Aseel S.
Wilson, Samantha A.
Mair, Frances S.
Buchan, Iain
Sheard, Sally B.
Atkinson, Paul
Joyce, Dan W.
Symon, Pyers
Walker, Lauren E.
PLOS ONE, 2024, 19 (03):
[34] Comparison of innovation policy and transfer of technology from public institutions in Japan, France, Germany and the United Kingdom
Angelino, Henri
Collier, Nigel
NII Journal, 2004, (08): : 53 - 90
[35] THE SOCIAL RIGHTS OF CITIZENS OF THE EUROPEAN UNION AND THE UNITED KINGDOM. FREE CIRCULATION OF WORKERS AND SOCIAL SECURITY AFTER THE BREXIT
Gallego Losada, Rocio
REVISTA GENERAL DEL DERECHO DEL TRABAJO Y DE LA SEGURIDAD SOCIAL, 2019, (52): : 92 - 135
[36] Towards Popular Sovereignty: A Response to Bruce Ackerman's 'Dis-United Kingdom: Constitutional Choices after Brexit'
White, Stuart
Barnett, Anthony
POLITICAL QUARTERLY, 2018, 89 (04): : 591 - 594
[37] How big a drop in agricultural exports to the United Kingdom after Brexit? Simulations for sensitive products of four Visegrad countries
Pawlak, Karolina
Hagemejer, Jan
Michalek, Jan Jakub
Dunin-Wasowicz, Maria
PLOS ONE, 2022, 17 (09):
[38] Policy Tensions in Regulatory Reform: Changes to Regulation of Health Professions in Australia, the United Kingdom, and Ontario, Canada
Leslie, Kathleen
Nelson, Sioban
Deber, Raisa
Gilmour, Joan
JOURNAL OF NURSING REGULATION, 2018, 8 (04) : 32 - 42
[39] Public Health Policy in the United Kingdom: After the War on Tobacco, Is a War on Alcohol Brewing?
Cairney, Paul
Studlar, Donley
WORLD MEDICAL & HEALTH POLICY, 2014, 6 (03): : 308 - 323
[40] DISASTER POLICY AND NUCLEAR LIABILITY - INSIGHTS FROM POST-CHERNOBYL AGRICULTURE IN THE UNITED-KINGDOM
KERR, WA
KWACZEK, AS
MOONEY, S
ENVIRONMENTAL MANAGEMENT, 1989, 13 (05) : 521 - 527

← 1 2 3 4 5 →